IL-6 ELISA Kit

Catalog No. ABIN577085

This Colorimetric ELISA kit is designed for the quantitative measurement of Human IL-6.

Quick Overview for IL-6 ELISA Kit (ABIN577085)

Target: IL-6 (IL6) (Interleukin 6 (IL6))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Application: ELISA

Product Details IL-6 ELISA Kit

Purpose: This IL-6 enzyme linked immunosorbent assay (ELISA) applies a technique called a quantitative sandwich immunoassay. The microtiter plate provided in this kit has been pre-coated with a monoclonal antibody specific to IL-6. Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated polyclonal antibody preparation specific for IL-6 and incubated. IL-6 if present, will bind and become immobilized by the antibody pre-coated on the wells and then be

Analytical Method: Quantitative

Sensitivity: The minimum detectable dose of IL-6 was determined by adding two standard deviations to the mean optical density value of the zero standard replicates and calculating the corresponding concentration from the standard curve. The minimum detectable dose using a standard curve generated with Calibrator Diluent I is 2.0 pg/mL and using Calibrator Diluent II is 1.75 pg/mL.

Components: Standards: 1 set/2 vials

Application Details

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Preservative: Without preservative

Target Details for IL-6

Target: IL-6 (IL6) (Interleukin 6 (IL6))

Alternative Name: Interleukin-6 (IL-6)

Background: Hepatitis B is an infection of the liver caused by the hepatitis B virus. Approximately 5-1% of adults and 9% of babies who are infected with HBV will go on to carry the virus for the rest of their lives. These people will pass the virus onto others. HBV is excreted in body fluids such as semen, saliva, blood and urine in persons with acute or chronic infection. The route of transmission can include homosexual or heterosexual activity, blood-borne exposure (needles, transfusion), mother-infant, close personal contact and even by consuming contaminated food or water. Thus, Hepatitis B has become a major public health concern. When HBV invades the body it causes liver damage through induction of auto-immunity. Liver cell injury results from cytotoxic T cell activity rather than viral cytotoxic activity. The principle screening test for detecting current (acute or chronic) HBV infection is the identification of HBsAg, an envelope lipoprotein. This is the first immunological marker, to appear in a patient's serum and exist in high quantities in the blood. Patients who are HBsAg positive develop chronic persistent hepatitis (CPH) and chronic active hepatitis (CAH). Patients with CPH usually remain in good health but those with CAH have progressive liver damage with the outcome being portal fibrosis, cirrhosis, or hepatocellular carcinoma. Screening for HBsAg is recommended for all donors, pregnant women and those individuals who at high risk. Presence of this marker is conclusive proof of HBV infection. YBL offers an immunoassay that can measure HBsAg through antigen-antibody interactions

Pathways: TLR Signaling, Hormone Transport, Negative Regulation of Hormone Secretion, Myometrial Relaxation and Contraction, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Regulation of Carbohydrate Metabolic Process, Autophagy, Cell RedoxHomeostasis, Cancer Immune Checkpoints, Inflammasome